Van ECK Associates Corp Decreases Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Van ECK Associates Corp cut its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 15.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,371,039 shares of the company’s stock after selling 249,603 shares during the quarter. Van ECK Associates Corp’s holdings in Elanco Animal Health were worth $20,428,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Treasurer of the State of North Carolina boosted its position in Elanco Animal Health by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 221,460 shares of the company’s stock valued at $2,489,000 after acquiring an additional 1,107 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Elanco Animal Health by 10.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,123 shares of the company’s stock valued at $181,000 after acquiring an additional 1,127 shares in the last quarter. Ieq Capital LLC boosted its position in Elanco Animal Health by 10.8% during the 3rd quarter. Ieq Capital LLC now owns 13,464 shares of the company’s stock valued at $151,000 after acquiring an additional 1,311 shares in the last quarter. AMG National Trust Bank boosted its position in Elanco Animal Health by 1.1% during the 3rd quarter. AMG National Trust Bank now owns 122,526 shares of the company’s stock valued at $1,377,000 after acquiring an additional 1,332 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its position in Elanco Animal Health by 2.6% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 61,540 shares of the company’s stock valued at $692,000 after acquiring an additional 1,546 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director R David Hoover acquired 20,000 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average price of $16.14 per share, with a total value of $322,800.00. Following the transaction, the director now directly owns 185,000 shares in the company, valued at approximately $2,985,900. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $13.16 on Wednesday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.35 and a current ratio of 2.75. The company has a 50 day moving average of $15.31 and a 200 day moving average of $13.85. Elanco Animal Health Incorporated has a twelve month low of $7.88 and a twelve month high of $16.88.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Monday, February 26th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The company had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. Elanco Animal Health’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.19 earnings per share. As a group, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Morgan Stanley boosted their price target on Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. The Goldman Sachs Group boosted their price target on Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research report on Tuesday, February 27th. Barclays boosted their price target on Elanco Animal Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Stifel Nicolaus raised Elanco Animal Health from a “hold” rating to a “buy” rating and boosted their price target for the stock from $13.00 to $20.00 in a research report on Friday, January 5th. Finally, TheStreet raised Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.